Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sotera Health (SHC) Gains from Investment Securities (2020 - 2025)

Sotera Health (SHC) has 6 years of Gains from Investment Securities data on record, last reported at $57.0 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 1166.37% year-over-year to $57.0 million; the TTM value through Dec 2025 reached $60.9 million, up 1274.73%, while the annual FY2025 figure was $60.9 million, 1274.73% up from the prior year.
  • Gains from Investment Securities reached $57.0 million in Q4 2025 per SHC's latest filing, up from $2.8 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $57.0 million in Q4 2025 and bottomed at -$24.1 million in Q3 2023.
  • Average Gains from Investment Securities over 5 years is $3.6 million, with a median of $857500.0 recorded in 2021.
  • The widest YoY moves for Gains from Investment Securities: up 4689.01% in 2022, down 382.29% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at $717000.0 in 2021, then crashed by 311.99% to -$1.5 million in 2022, then plummeted by 114.08% to -$3.3 million in 2023, then surged by 238.35% to $4.5 million in 2024, then soared by 1166.37% to $57.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $57.0 million in Q4 2025, $2.8 million in Q3 2025, and -$2.5 million in Q2 2025.